# US 2025/0154511 A1 · Products and Methods for Treatment of Amyotrophic Lateral Sclerosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0154511 A1
- Document ID: US20250154511A1
- Status: Published application
- Kind: A1
- Application number: 19/028,018
- Filed: 2025-01-17
- Published: 2025-05-15
- Earliest claimed: 2013-08-27
- Assignees: Research Institute At Nationwide Children's Hospital; Ludwig Institute for Cancer Research
- Applicants: Research Institute At Nationwide Children's Hospital; Ludwig Institute for Cancer Research
- Inventors: Brian K. Kaspar; Kevin Foust; Don W. Cleveland
- Web page: https://patentgrep.com/patent/US20250154511A1

## CPC

- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 9/0089: {acting on superoxide as acceptor (1.15)}
- C12N 15/86: Viral vectors
- C12Y 115/01001: Superoxide dismutase (1.15.1.1)
- A61P 25/02: for peripheral neuropathies
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/531: Stem-loop; Hairpin
- C12N 2320/32: Special delivery means, e.g. tissue-specific
- C12N 2750/14043: viral genome or elements thereof as genetic vector
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Y: ENZYMES

## Abstract

The present invention relates to RNA-based methods for inhibiting the expression of the superoxide dismutase 1 (SOD-1) gene. Recombinant adeno-associated viruses of the invention deliver DNAs encoding RNAs that knock down the expression of SOD-1. The methods have application in the treatment of amyotrophic lateral sclerosis.

## Claims

### Claim 1

A recombinant adeno-associated virus comprising the superoxide dismutase 1 (SOD1) shRNA-encoding DNA:
(SEQ ID NO: 1)
GCATCATCAATTTCGAGCAGAAGGAA,
(SEQ ID NO: 2)
GAAGCATTAAAGGACTGACTGAA,
(SEQ ID NO: 3)
CTGACTGAAGGCCTGCATGGATT,
(SEQ ID NO: 4)
CATGGATTCCATGTTCATGA,
(SEQ ID NO: 5)
GCATGGATTCCATGTTCATGA,
(SEQ ID NO: 6)
GGTCTGGCCTATAAAGTAGTC,
(SEQ ID NO: 7)
GGGCATCATCAATTTCGAGCA,
(SEQ ID NO: 8)
GCATCATCAATTTCGAGCAGA,
(SEQ ID NO: 9)
GCCTGCATGGATTCCATGTTC,
(SEQ ID NO: 10)
GGAGGTCTGGCCTATAAAGTA,
(SEQ ID NO: 11)
GATTCCATGTTCATGAGTTTG,
(SEQ ID NO: 12)
GGAGATAATACAGCAGGCTGT,
(SEQ ID NO: 13)
GCTTTAAAGTACCTGTAGTGA,
(SEQ ID NO: 14)
GCATTAAAGGACTGACTGAAG,
(SEQ ID NO: 1)
GCATCATCAATTTCGAGCAGAAGGAA,
(SEQ ID NO: 2)
GAAGCATTAAAGGACTGACTGAA,
(SEQ ID NO: 3)
CTGACTGAAGGCCTGCATGGATT,
(SEQ ID NO: 4)
CATGGATTCCATGTTCATGA,
(SEQ ID NO: 5)
GCATGGATTCCATGTTCATGA,
(SEQ ID NO: 6)
GGTCTGGCCTATAAAGTAGTC,
(SEQ ID NO: 7)
GGGCATCATCAATTTCGAGCA,
(SEQ ID NO: 8)
GCATCATCAATTTCGAGCAGA,
(SEQ ID NO: 9)
GCCTGCATGGATTCCATGTTC,
(SEQ ID NO: 10)
GGAGGTCTGGCCTATAAAGTA,
(SEQ ID NO: 11)
GATTCCATGTTCATGAGTTTG,
(SEQ ID NO: 12)
GGAGATAATACAGCAGGCTGT,
(SEQ ID NO: 13)
GCTTTAAAGTACCTGTAGTGA,
(SEQ ID NO: 14)
GCATTAAAGGACTGACTGAAG,
(SEQ ID NO: 15)
TCATCAATTTCGAGCAGAA,
(SEQ ID NO: 16)
TCGAGCAGAAGGAAAGTAA,
(SEQ ID NO: 17)
GCCTGCATGGATTCCATGT,
(SEQ ID NO: 18)
TCACTCTCAGGAGACCATT,
or
(SEQ ID NO: 19)
GCTTTAAAGTACCTGTAGT,
wherein the recombinant adeno-associated virus genome lacks rep and cap genes.

### Claim 2 (depends on 1)

A composition comprising the recombinant adeno-associated virus of claim 1.

### Claim 3 (depends on 1, 2)

A method of inhibiting expression of mutant SOD1 in a cell comprising contacting the cell with a recombinant adeno-associated virus of claim 1 or the composition of claim 2.

### Claim 4

A method of delivering the SOD1 shRNA-encoding DNA GCATCATCAATTTCGAGCAGAAGGAA (SEQ ID NO:1) to a subject in need thereof, comprising administering to the subject a recombinant adeno-associated virus comprising the SOD1 shRNA-encoding DNA GCATCATCAATTTCGAGCAGAAGGAA (SEQ ID NO:1), wherein the recombinant adeno-associated virus genomre lacks rep and cap genes.

### Claim 5

A method of delivering the SOD1 shRNA-encoding DNA GAAGCATTAAAGGACTGACTGAA (SEQ ID NO:2) to a subject in need thereof, comprising administering to the subject a recombinant adeno-associated virus comprising the SOD1 shRNA-encoding DNA GAAGCATTAAAGGACTGACTGAA (SEQ ID NO:2), wherein the recombinant adeno-associated virus genome lacks rep and cap genes.

### Claim 6

A method of delivering the SOD1 shRNA-encoding DNA CTGACTGAAGGCCTGCATGGATT (SEQ ID NO:3) to a subject in need thereof, comprising administering to the subject a recombinant adeno-associated virus comprising the SOD1 shRNA-encoding DNA CTGACTGAAGGCCTGCATGGATT (SEQ ID NO:3), wherein the recombinant adeno-associated virus genome lacks rep and cap genes.

### Claim 7

A method of delivering the SOD1 shRNA-encoding DNA CATGGATTCCATGTTCATGA (SEQ ID NO:4) to a subject in need thereof, comprising administering to the subject a recombinant adeno-associated virus comprising the SOD1 shRNA-encoding DNA CATGGATTCCATGTTCATGA (SEQ ID NO:4), wherein the recombinant adeno-associated virus gemone lacks rep and cap genes.

### Claim 8

A method of treating amyotrophic lateral sclerosis (ALS) comprising administering a recombinant adeno-associated virus comprising the SOD1 shRNA-encoding DNA GCATCATCAATTTCGAGCAGAAGGAA (SEQ ID NO:1), wherein the recombinant adeno-associated virus genome lacks rep and cap genes.

### Claim 9

A method of treating ALS comprising administering a recombinant adeno-associated virus comprising the SOD1 shRNA-encoding DNA GAAGCATTAAAGGACTGACTGAA (SEQ ID NO:2), wherein the recombinant adeno-associated virus lacks rep and cap genes.

### Claim 10

A method of treating ALS comprising administering a recombinant adeno-associated virus comprising the SOD1 shRNA-encoding DNA CTGACTGAAGGCCTGCATGGATT (SEQ ID NO:3), wherein the recombinant adeno-associated virus lacks rep and cap genes.

### Claim 11

A method of treating ALS comprising administering a recombinant adeno-associated virus comprising the SOD1 shRNA-encoding DNA CATGGATTCCATGTTCATGA (SEQ ID NO:4), wherein the recombinant adeno-associated virus lacks rep and cap genes.
